10 January 2020
Visiongain has launched a new pharma report: Global Bioreactors Market 2020-2030: 5L-20L, 20L-200L, 200L-1500L, Above 1500L, Single-Use, Glass, Stainless Steel, Lab-Scale, Pilot-Scale, Full-Scale, R&D Departments, Biopharmaceutical Manufacturers, Contract Research Organizations, Other End-Users.
Bioreactors are vessels or apparatus that are designed to provide a controlled environment for the optimal growth of microbes. The primary factor boosting the demand of bioreactors includes increased consumer demand for biopharmaceuticals. Biopharmaceuticals allows the modulation of physiological processes at the cellular level, hence, are effective in the treatment of disorders that are tough to be treated by conventional drugs.
The lead analyst of the report commented "Factors driving the bioreactors market growth include rise in the rate of adoption of single-use technologies, growing demand for biopharmaceuticals, rising penetration of biosimilars, and growing aging population. However, regulatory challenges pertaining to single-use bioreactors and issues concerning leachable and extractable linked to single-use bags are some of the factors hampering the growth of bioreactors market."
Leading companies featured in the report include Applikon Biotechnology Inc. (U.S.), BBI-Biotech GmbH (Germany), Bioengineering AG (Switzerland), Danaher Corporation (U.S), Eppendorf AG (Germany), GE Healthcare (A subsidiary of General Electric Company) (U.S.), Merck KGaA (Germany) and other companies.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
The 431-page report provides clear detailed insight into the generic drugs market. Discover the key drivers and challenges affecting the market.
03 July 2020
Where is the Clinical Workflow Solutions market heading? If you are involved in this sector you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
03 July 2020
With the growing burden of rare diseases around the world, there has been a rise and advancement in the therapy development of these types of diseases. While the fact remains that over 90% of these diseases lack approval for treatment and the total number of terminal rare diseases to receive the first treatment every year remains low.
01 July 2020
The market growth is attributed to the growing adoption of big data and AI in data management and monitoring of clinical information in health care.